Theriva Biologics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Theriva Biologics initiated the VIRAGE2 Phase 2a trial dosing first patients with VCN-01 in metastatic pancreatic cancer, testing more frequent (≥3 doses ~2 months apart) versus prior 2-dose regimen; enrollment of 6 evaluable patients expected to complete H2 2026 with results by Q3 2027. Cash position: $11.3M as of June 30, 2026 (down $1.7M from Dec 31, 2025), with runway into Q1 2027; six-month net loss was $5.3M. Share count increased to 45.9M from 35.7M (28.6% dilution year-over-year).
Why this rating
Clinical progress on lead asset materially de-risks Phase 3 path, but severe cash constraint (runway ~6 months at burn rate) and massive share dilution create existential financing urgency for $3.9M market-cap company.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.